171 results on '"Roughead, Elizabeth E"'
Search Results
2. Data-Driven Interventions for an Emergency Preparedness System: A National Experience in Australia.
- Author
-
ANDRADE, Andre Q., KERR, Mhairi, and Roughead, Elizabeth E.
- Subjects
MENTAL illness prevention ,CIVIL defense ,DIGITAL technology ,CHRONIC diseases ,COMMUNITY health services ,CONFERENCES & conventions ,MEDICAL care ,EMERGENCY management ,PSYCHOLOGY of veterans ,MEDICAL emergencies ,COMPARATIVE studies ,PRIMARY health care ,COMMUNICATION ,NATURAL disasters ,DESCRIPTIVE statistics ,AT-risk people ,RESEARCH funding ,DATA analysis software ,COVID-19 pandemic - Abstract
Natural disasters and health emergencies disproportionally affect vulnerable populations causing disruptions to usual care and increasing chronic disease burden. Data and digital technologies are important tools to identify and mitigate indirect effects of emergencies. In this paper, we describe the methods used in the development of a series of digital emergency preparedness interventions to mitigate the direct and indirect consequences of the COVID-19 pandemic in the veteran community in Australia. The case studies demonstrate the use of data for surveillance, patient phenotyping, data-driven decision support and stakeholder communication in primary care. The intervention successfully increased appropriate healthcare use by vulnerable individuals and could be expanded to other populations. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. From the city to the bush: Increases in patient co-payments for medicines have impacted on medicine use across Australia
- Author
-
Kemp, Anna, Glover, John, Preen, David B, Bulsara, Max, Semmens, James, and Roughead, Elizabeth E
- Published
- 2013
4. How Much Do We Spend on Prescription Medicines?: Out-of-Pocket Costs for Patients in Australia and Other OECD Countries
- Author
-
Kemp, Anna, Preen, David B, Glover, John, Semmens, James, and Roughead, Elizabeth E
- Published
- 2011
5. Clinical pharmacy: Medicine use among the elderly before and after hip fracture
- Author
-
Leach, Michael J, Roughead, Elizabeth E, Hayward, Kylee, Editor, and Jenkins, Natalie, Editor
- Published
- 2014
6. Precision public-health intervention for care coordination: a real-world study.
- Author
-
Andrade, Andre Q, Calabretto, Jean-Pierre, Pratt, Nicole L, Kalisch-Ellett, Lisa M, Le Blanc, Vanessa T, and Roughead, Elizabeth E
- Subjects
INTEGRATED health care delivery ,COVID-19 pandemic ,PROPORTIONAL hazards models ,GENERAL practitioners ,DIGITAL technology ,CLINICAL trials - Abstract
Background: Health emergencies disproportionally affect vulnerable populations. Digital tools can help primary care providers find, and reach, the right patients. Aim: To evaluate whether digital interventions delivered directly to GPs' clinical software were more effective at promoting primary care appointments during the COVID-19 pandemic than interventions delivered by post. Design and setting: Real-world, non-randomised, interventional study involving GP practices in all Australian states. Method: Intervention material was developed to promote care coordination for vulnerable older veterans during the COVID-19 pandemic, and sent to GPs either digitally to the clinical practice software system or in the post. The intervention material included patient-specific information sent to GPs to support care coordination, and education material sent via post to veterans identified in the administrative claims database. To evaluate the impact of intervention delivery modalities on outcomes, the time to first appointment with the primary GP was measured; a Cox proportional hazards model was used, adjusting for differences and accounting for pre-intervention appointment numbers. Results: The intervention took place in April 2020, during the first weeks of COVID-19 social distancing restrictions in Australia. GPs received digital messaging for 51 052 veterans and postal messaging for 26 859 veterans. The digital group was associated with earlier appointments (adjusted hazard ratio 1.38 [1.34 to 1.41]). Conclusion: Data-driven digital solutions can promote care coordination at scale during national emergencies, opening up new perspectives for precision public-health initiatives. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Medicine-Induced Acute Kidney Injury Findings from Spontaneous Reporting Systems, Sequence Symmetry Analysis and a Case-Control Study with a Focus on Medicines Used in Primary Care.
- Author
-
Roughead, Elizabeth E., Kerr, Mhairi, Moffat, Anna, Kassie, Gizat M., and Pratt, Nicole
- Subjects
- *
NAPROXEN , *SPIRONOLACTONE , *FUROSEMIDE , *IBUPROFEN , *CIPROFLOXACIN , *AMPHOTERICIN B , *DICLOFENAC , *CASE-control method , *SULFAMETHOXAZOLE , *PRIMARY health care , *SIMVASTATIN , *OMEPRAZOLE , *METFORMIN , *DRUG side effects , *RAMIPRIL , *AMLODIPINE , *ACUTE kidney failure , *TRIMETHOPRIM - Abstract
Introduction: Primary care provides an opportunity to prevent community acquired, medicine or drug-induced acute kidney injury. One of the barriers to proactive prevention of medicine-induced kidney injury in primary care is the lack of a list of nephrotoxic medicines that are most problematic in primary care, particularly one that provides a comparison of risks across medicines.Objective: The aim of this study was to consolidate evidence on the risks associated with medicines and acute kidney injury, with a focus on medicines used in primary care.Method: We searched the MEDLINE and EMBASE databases to identify published studies of all medicines associated with acute kidney injury identified from spontaneous report data. For each medicine positively associated with acute kidney injury, as identified from spontaneous reports, we implemented a sequence symmetry analysis (SSA) and a case-control design to determine the association between the medicine and hospital admission with a primary diagnosis of acute kidney injury (representing community-acquired acute kidney injury). Administrative claims data held by the Australian Government Department of Veterans' Affairs for the study period 2005-2019 were used.Results: We identified 89 medicines suspected of causing acute kidney injury based on spontaneous report data and a reporting odds ratio above 2, from Japan, France and the US. Spironolactone had risk estimates of 3 or more based on spontaneous reports, SSA and case-control methods, while furosemide and trimethoprim with sulfamethoxazole had risk estimates of 1.5 or more. Positive association with SSA and spontaneous reports, but not case control, showed zoledronic acid had risk estimates above 2, while candesartan telmisartan, simvastatin, naproxen and ibuprofen all had risk estimates in SSA between 1.5 and 2. Positive associations with case-control and spontaneous reports, but not SSA, were found for amphotericin B, omeprazole, metformin, amlodipine, ramipril, olmesartan, ciprofloxacin, valaciclovir, mycophenolate and diclofenac. All with the exception of metformin and omeprazole had risk estimates above 2.Conclusion: This research highlights a number of medicines that may contribute to acute injury; however, we had an insufficient sample to confirm associations of some medicines. Spironolactone, furosemide, and trimethoprim with sulfamethoxazole are medicines that, in particular, need to be used carefully and monitored closely in patients in the community at risk of acute kidney injury. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
8. Effect of an ongoing pharmacist service to reduce medicine-induced deterioration and adverse reactions in aged-care facilities (nursing homes): a multicentre, randomised controlled trial (the ReMInDAR trial).
- Author
-
Roughead, Elizabeth E, Pratt, Nicole L, Parfitt, Gaynor, Rowett, Debra, Kalisch-Ellett, Lisa M, Bereznicki, Luke, Merlin, Tracy, Corlis, Megan, Kang, Ai Choo, Whitehouse, Joseph, Bilton, Rebecca, Schubert, Camille, Torode, Stacey, Kelly, Thu-Lan, Andrade, Andre Q, Post, Dannielle, Dorj, Gereltuya, Cousins, Justin, Williams, Mackenzie, and Lim, Renly
- Subjects
- *
PREVENTION of drug side effects , *OCCUPATIONAL roles , *RESEARCH , *COGNITION disorders , *GRIP strength , *PARASYMPATHOMIMETIC agents , *BODY weight , *CONFIDENCE intervals , *POLYPHARMACY , *MOVEMENT disorders , *NURSING care facilities , *MEDICATION therapy management , *RANDOMIZED controlled trials , *ACCELEROMETRY , *QUALITY of life , *DESCRIPTIVE statistics , *STATISTICAL sampling - Abstract
Objective To assess the effectiveness of a pharmacist-led intervention using validated tools to reduce medicine-induced deterioration and adverse reactions. Design and setting Multicenter, open-label parallel randomised controlled trial involving 39 Australian aged-care facilities. Participants Residents on ≥4 medicines or ≥1 anticholinergic or sedative medicine. Intervention Pharmacist-led intervention using validated tools to detect signs and symptoms of medicine-induced deterioration which occurred every 8 weeks over 12 months. Comparator Usual care (Residential Medication Management Review) provided by accredited pharmacists. Outcomes Primary outcome was change in Frailty Index at 12 months. Secondary outcomes included changes in cognition, 24-hour movement behaviour by accelerometry, grip strength, weight, adverse events and quality of life. Results 248 persons (median age 87 years) completed the study; 120 in the interventionand, 128 in control arms. In total 575 pharmacist, sessions were undertaken in the intervention arm. There was no statistically significant difference for change in frailty between groups (mean difference: 0.009, 95% CI: −0.028, 0.009, P = 0.320). A significant difference for cognition was observed, with a mean difference of 1.36 point change at 12 months (95% CI: 0.01, 2.72, P = 0.048). Changes in 24-hour movement behaviour, grip strength, adverse events and quality of life were not significantly different between groups. Point estimates favoured the intervention arm at 12 months for frailty, 24-hour movement behaviour and grip strength. Conclusions The use of validated tools by pharmacists to detect signs of medicine-induced deterioration is a model of practice that requires further research, with promising results from this trial, particularly with regards to improved cognition. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. The Extent of Medication-Related Hospital Admissions in Australia: A Review from 1988 to 2021.
- Author
-
Lim, Renly, Ellett, Lisa M. Kalisch, Semple, Susan, and Roughead, Elizabeth E.
- Subjects
MEDICATION abuse ,HOSPITAL admission & discharge ,PUBLIC health ,COST - Abstract
Introduction: Medication-related problems often lead to patient harm. This paper aims to review the Australian literature to determine the overall incidence, severity and preventability of medication-related hospital admissions, as well as providing a national estimate on their extent and cost. Methods: The first part of the paper includes a literature search to identify studies that provided estimates of medication-related problems that caused hospital admissions. Incidence of medication-related hospital admissions, type of medication-related problem contributing to admission (e.g. adverse medicine reaction) and method used to estimate incidence (e.g. chart review) were extracted. Data on severity and preventability of the admissions were extracted where available. The second part of the paper involves use of methodological triangulation to estimate the extent and cost of medication-related hospital admission. Median estimates used to assess medication-related hospital admissions and the 2019–2020 national hospital admissions data were used to calculate the national estimate on the extent of medication-related hospital admission. Costs were also estimated. Results: Seventeen studies provided estimates on the extent of medication-related hospital admissions as assessed using medication chart review. The median incidence of 2.5% (interquartile range [IQR] 0.6%) as a proportion of all hospital admissions suggests 275,000 hospital admissions annually in Australia are medication related. The median incidence of 9% (IQR 3.9%) of emergency admissions suggests that 270,000 admissions annually are medication related. Eight studies provided estimates of the extent of medication-related hospital admissions identified from administrative health data; the median incidence of 1.7% with an under-reporting rate of 82% suggests 280,000 hospital admissions annually are medication related. Triangulation of results suggests that at least 250,000 hospital admissions annually in Australia are medication related, with an estimated cost of 1.4 billion Australian dollars (AUD$). Five studies assessed severity, and nine studies assessed preventability. Preventability estimates suggest two-thirds of medication-related hospital admissions are potentially preventable. Conclusions: We estimated that 250,000 hospital admissions in Australia are medication related, with an annual cost of AUD$1.4 billion to the healthcare system. Two-thirds of medication-related hospital admissions are potentially preventable. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Medication‐related hospital admissions in aged care residents.
- Author
-
Kalisch Ellett, Lisa M., Kassie, Gizat M., Caughey, Gillian E., Pratt, Nicole L., Ramsay, Emmae N., and Roughead, Elizabeth E.
- Subjects
CLINICAL drug trials ,KEY performance indicators (Management) ,RETROSPECTIVE studies ,HOSPITAL care ,RESIDENTIAL care ,CLINICAL medicine ,ACCIDENTAL falls ,RESEARCH funding ,DRUG side effects ,PATIENT compliance ,MEDICAL care of veterans ,HEART failure ,OLD age - Abstract
Objective: To determine the prevalence of medication‐related hospitalisations preceded by potentially suboptimal processes of care in aged care residents. Method: We conducted a retrospective analysis of administrative claims data from the Australian Government Department of Veterans' Affairs (DVA). We identified all hospital admissions for aged care residents between 1 July 2014 and 30 June 2019. The proportion of hospital admissions preceded by potentially suboptimal medication‐related processes of care was determined. Results: A total of 18 874 hospitalisations were included, and 46% were preceded by potentially suboptimal medication‐related care. One‐quarter of fracture admissions occurred in residents at risk of fracture who were not using a medicine to prevent fracture, and 87% occurred in residents using falls‐risk medicines. Thirty per cent of heart failure admissions occurred in patients who were not using an angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker. Conclusion: Nearly half of hospital admissions were preceded by potentially suboptimal medication‐related processes of care. Interventions to improve use of medicines for aged care residents in these areas are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Evaluation of Renal Function Testing in Older Australian Veterans Dispensed Medicines that Require Renal Function Monitoring.
- Author
-
Kalisch Ellett, Lisa M., Kassie, Gizat M., Ramsay, Emmae N., Pratt, Nicole L., and Roughead, Elizabeth E.
- Subjects
KIDNEY function tests ,CONFIDENCE intervals ,FUNCTIONAL status ,RETROSPECTIVE studies ,DIABETES ,KIDNEY diseases ,DRUGS ,DRUG monitoring ,DISEASE prevalence ,CHI-squared test ,DESCRIPTIVE statistics ,VETERANS ,ODDS ratio ,DATA analysis software ,CREATININE ,HEART failure ,OLD age - Abstract
Introduction: Renal function testing should be performed prior to initiating medicines that require dose adjustment in renal impairment, with ongoing monitoring in continued use, particularly in older people. There is little evidence regarding the extent to which renal function monitoring is performed in older Australians dispensed medicines requiring renal function monitoring. Objective: The aim of this study was to determine the extent of renal function testing in older people dispensed medicines requiring renal function monitoring. Methods: A retrospective analysis of administrative claims data from the Australian Government Department of Veterans' Affairs was conducted for people aged 65 years or older who were dispensed one or more medicines requiring renal function monitoring, from 1 June 2019 to 30 September 2019, to investigate the proportion of people with a claim for a pathology test that included creatinine levels in the 6–12 months before or after dispensing of a medicine requiring renal function monitoring. Results: There were 100,113 people who were dispensed at least one medicine requiring renal function monitoring during the study period, of whom 15% had a history of renal impairment and 16% had diabetes mellitus. Sixty-one percent had a claim for a test in the prior 6 months; this increased to 80% of participants with a claim for a test in the prior 12 months. The rate of claims for testing was lower in aged care facility residents compared with people living in the community (54% vs 62% in the previous 6 months; p < 0.001), and was higher in people with diabetes (75% vs 58%; p < 0.001), history of renal impairment (91% vs 59%; p < 0.001) or heart failure (77% vs 60%; p < 0.001) compared with those without these conditions. Conclusion: Medicines that require renal function monitoring are commonly used in older Australians, and while the majority have claims for tests that include renal function, some are missing out. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Post-market utilization patterns of Alzheimer's disease treatments in South Korea: comparison with countries with universal health coverage.
- Author
-
Lee, Hye-Jae, Roughead, Elizabeth E., Han, Euna, Lee, Jihye, and Kalisch Ellett, Lisa
- Subjects
- *
ALZHEIMER'S disease , *GALANTHAMINE , *MEMANTINE , *CHOLINESTERASE inhibitors , *POPULATION geography , *MEDICAL care costs , *MARKETING , *COMPARATIVE studies , *HEALTH insurance reimbursement , *PATENTS , *PHARMACEUTICAL arithmetic , *NATIONAL health insurance , *DONEPEZIL , *DRUG utilization ,EVALUATION of drug utilization - Abstract
Purpose: This study aimed to compare the utilization of Alzheimer's disease (AD) treatments, donepezil, galantamine, rivastigmine, and memantine, in Korea with Australia and other countries with universal health coverage. Methods: Reimbursement criteria and the patent status of four AD treatments in Korea and Australia were reviewed. The monthly spending and utilization of the treatments were extracted from the national electronic database in Korea and Australia. The defined daily dose per 1000 elderly population per day (DDD/1000e/day) were calculated from July 2008 to June 2019. Annual cost trends of Norway and England were compared with Korea and Australia. Results: With the highest share of the use of donepezil in both countries, the cost and utilization of AD treatments in Korea increased more rapidly and remained higher than Australia. The cost of AD treatments in Korea increased by 15.5% every year during the study period, while the spending of the same drugs in Australia decreased by 10.5% annually. The utilization in DDD/1000e/day of AD treatments in Korea increased by 18.3% annually compared with 1.4% in Australia. When compared with Norway and England, countries with similar universal health coverage (UHC) system and elderly polupation, the cost of AD treatments in Korea was still higher with the opposite trend from other countries. Conclusions: Despite the similar UHC systems, there were considerable differences in the post-market utilization of AD treatments in Korea from Australia and other countries. This results can be attributed to differences in re-assessment system, pricing and reimbursement policies, and prescribing culture. This study provides a baseline to explore more comprehensive cross-country studies on rational use of medicines. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Initiation and continuation of antipsychotic medicines in older people following non-psychiatric hospital admission.
- Author
-
Kalisch Ellett, Lisa M., Pratt, Nicole L., Apajee, Jemisha, and Roughead, Elizabeth E.
- Subjects
MENTAL illness drug therapy ,ANTIPSYCHOTIC agents ,CONTINUUM of care ,DELIRIUM ,DEMENTIA ,HOSPITAL admission & discharge ,PATIENTS ,TREATMENT effectiveness ,RETROSPECTIVE studies - Abstract
Background Internationally, antipsychotics are frequently initiated during hospital admission for older patients and use often continues post-discharge without indication. We located no Australian studies on this topic. Objective to identify the hospital admissions (excluding psychosis) associated with antipsychotic initiation and continuation in older Australians. Setting Australian Government Department of Veterans' Affairs. Method Retrospective analysis of administrative claims data for people admitted to hospital from 1 January 2014 to 31 December 2014, aged ≥ 65 years, who were antipsychotic naïve. Main outcome measure number of admissions associated with antipsychotic initiation, and the major diagnosis groups for these admissions. Where antipsychotics were initiated, we determined the time to cessation of antipsychotics after discharge. Results There were 142,009 hospital admissions for 66,415 people with a median age of 86 years. 921 (0.65%) admissions were associated with antipsychotic initiation, most commonly where the primary diagnoses were for mental and behavioural disorders excluding psychosis (17.8%) and injuries (16%). Fourteen percent of antipsychotic initiations were for primary diagnoses of delirium or dementia. When secondary diagnoses were considered, 55% of antipsychotic initiations were associated with delirium, dementia or both. The median duration of use among people who used antipsychotics was 132 days, and 40% continued use until death or one year follow-up. Conclusion Initiation of antipsychotics during hospital admissions was not frequent in this Australian population. Amongst those who did initiate antipsychotics, for almost half no diagnosis corresponding with an approved indication for use was recorded and long-term use of up to one year was common. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Use of medicines that may precipitate delirium prior to hospitalisation in older Australians with delirium: An observational study.
- Author
-
Kassie, Gizat M., Kalisch Ellett, Lisa M., Nguyen, Tuan A., and Roughead, Elizabeth E.
- Subjects
DIAGNOSIS of delirium ,RISK of delirium ,VETERANS' societies ,ANTIDEPRESSANTS ,DRUG utilization ,HOSPITAL care ,MEDICATION errors ,NARCOTICS ,SCIENTIFIC observation ,RISK-taking behavior ,TRANQUILIZING drugs ,DISEASE prevalence ,RETROSPECTIVE studies ,OLD age - Abstract
Objective: To assess the use of medicines associated with delirium prior to hospital admission in older Australian patients with a recorded diagnosis of delirium. Methods: A retrospective observational study was conducted using de‐identified data from the Australian Government Department of Veterans' Affairs Health Care Claims Database. The prevalence of use of medicines associated with delirium was determined in people 65 years or older with a delirium diagnosis. Results: Three‐quarters of the total 22 923 older patients included were taking at least one medicine associated with delirium, the median number of medications per patient was two (interquartile range, 1‐3). The most frequently used medicines known to be associated with delirium were psycholeptics, opioids and tricyclic antidepressants. Conclusion: A substantial proportion of older hospitalised patients with a delirium diagnosis were taking medicines known or suspected to precipitate delirium prior to admission. There may be an opportunity to decrease medication‐associated delirium by reducing use of risky medication. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. Mesh use in urogynaecological procedures between 2005 and 2016: An Australian cohort study.
- Author
-
Gillam, Marianne H., Kerr, Mhairi, Pratt, Nicole L., Lim, Renly, and Roughead, Elizabeth E.
- Subjects
PELVIC organ prolapse ,CONFIDENCE intervals ,UROLOGICAL surgery ,LONGITUDINAL method ,RESEARCH funding ,TIME series analysis ,URINARY stress incontinence ,LOGISTIC regression analysis ,DATA analysis software ,DESCRIPTIVE statistics ,SURGICAL meshes ,SURGERY - Abstract
Background: Pelvic organ prolapse (POP) and stress urinary incontinence (SUI) are common conditions. The use of mesh in the surgical treatment of these conditions in Australia is unclear. Aim: To examine the use of mesh in POP and SUI procedures in an Australian national cohort of older women. Methods: We conducted a population‐based cohort study using data from the Australian Government Department of Veterans' Affairs (DVA) database. The cohort consisted of older women who had POP and SUI procedures between 1 July, 2005 and 31 December, 2016. Women who received mesh were identified by matching device billing codes with the Australian Government's Prosthesis List. Results: In total, 3129 women experienced 3472 hospitalisations for POP and SUI procedures, with 74% of the women aged 75 years and older. There were 2276 (66%) hospitalisations with single POP repairs, 608 (18%) with single SUI procedures and 588 (17%) with concomitant POP and SUI procedures. Mesh was used in 23% of single procedures for POP, in 89% of single procedures for SUI and in 90% of concomitant POP and SUI procedures. The use of mesh in POP procedures decreased from a peak of 33% in 2008 down to 8% by 2016, whereas the use of mesh in SUI procedures increased from 77% in 2006 to 91% by 2016. Conclusion: Mesh was commonly used in SUI procedures, whereas use of mesh in POP repair was less common and the use decreased rapidly after 2011, when warnings about use of mesh in POP were first issued. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. Knowledge of Australian hospital pharmacists regarding delirium in elderly patients.
- Author
-
Kassie, Gizat M., Kalisch Ellett, Lisa M., Nguyen, Tuan A., and Roughead, Elizabeth E.
- Subjects
RISK of delirium ,DELIRIUM ,NEWSLETTERS ,PHARMACISTS ,PROFESSIONS ,QUESTIONNAIRES ,SURVEYS ,CROSS-sectional method ,OLD age ,PREVENTION - Abstract
Abstract: Background: Delirium is a serious condition in which medications are just one of a number of potential predisposing or precipitating factors. Adequate knowledge of delirium among all healthcare professionals, including pharmacists, may assist in effective prevention and management. However, little is known about the knowledge of pharmacists regarding delirium. Aim: To assess Australian hospital pharmacists' knowledge of risk factors, symptoms, prevention and treatment of delirium in elderly patients. Method: A cross‐sectional survey was conducted via a web‐based questionnaire to collect information on participants' demographics, knowledge of delirium risk factors, symptoms, prevention and treatment. A link to the survey was included in the newsletters of The Society of Hospital Pharmacists of Australia, Australasian Delirium Association and New South Wales Therapeutic Advisory Group and distributed to hospital pharmacists in Australia via email. Results: One‐hundred and six responses from hospital pharmacists were available for analysis. Nine of 11 questions assessing basic knowledge were correctly answered by more than half of respondents. Seven of the eight questions related to delirium prevention strategies were correctly answered by more than half of pharmacists. However, only three of the eight questions about risk factors for delirium were answered correctly by more than half of pharmacists. Conclusion: Pharmacists' basic knowledge about delirium and prevention strategies was good; however, their knowledge of risk factors and symptoms of delirium needs to be improved. Delirium‐specific educational programs for pharmacists should be considered for improving their knowledge and understanding regarding delirium. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
17. Posttraumatic Stress Disorder, Antipsychotic Use and Risk of Dementia in Veterans.
- Author
-
Roughead, Elizabeth E., Pratt, Nicole L., Kalisch Ellett, Lisa M., Ramsay, Emmae N., Barratt, John D., Morris, Philip, and Killer, Graeme
- Subjects
- *
POST-traumatic stress disorder , *DEMENTIA risk factors , *MENTAL health of veterans , *ANTIPSYCHOTIC agents , *VETERANS , *RETROSPECTIVE studies , *COHORT analysis , *PATIENTS , *CONFIDENCE intervals , *HOSPITAL care , *SCIENTIFIC observation , *PROPORTIONAL hazards models , *DESCRIPTIVE statistics ,AUSTRALIA. Dept. of Veterans' Affairs - Abstract
Objectives To examine the risk of dementia associated with posttraumatic stress disorder ( PTSD) and the contribution of antipsychotic use to this risk. Design Retrospective cohort study Setting Australia. Administrative claims data from the Australian Government Department of Veterans' Affairs were used. Participants Male Vietnam veterans aged 55 to 65 at baseline (2001-02) with no preexisting dementia diagnosis (N = 15,612). Measurements The association between PTSD and dementia was assessed over 12 years of follow-up. Dementia was identified as a hospital diagnosis, dementia record in service disability data, or dispensing of medicines for dementia. Cox-proportional hazards models were used, with age as the time-scale. Results were stratified according to baseline antipsychotic use. Results No greater risk of dementia was observed with PTSD. In veterans who received antipsychotics, dementia risk was significantly higher than in those who did not (hazard ratio ( HR) = 2.1, 95% confidence interval ( CI) = 1.4-3.3). Dementia risk was significantly greater in veterans hospitalized for PTSD who received antipsychotics ( HR = 2.2, 95% CI = 1.1-4.6) and veterans without PTSD who received antipsychotics ( HR = 4.3, 95% CI = 2.1-8.6) than in those without PTSD with no antipsychotic use. Conclusion Antipsychotic use may be a contributor to dementia risk. These findings should be interpreted with caution because the study design was observational. Further research using prospective study designs in settings where diagnostic data, cognitive function, and disease severity are available are required. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
18. Heart failure after conventional metal-on-metal hip replacements.
- Author
-
GILLAM, Marianne H., PRATT, Nicole L., INACIO, Maria C. S., ROUGHEAD, Elizabeth E., SHAKIB, Sepehr, NICHOLLS, Stephen J., and GRAVES, Stephen E.
- Subjects
HEART failure treatment ,OSTEOARTHRITIS treatment ,ACETABULUM (Anatomy) ,CONFIDENCE intervals ,FRACTURE fixation ,HEART failure ,HOSPITAL care ,ORTHOPEDIC apparatus ,EVALUATION of medical care ,METALS ,NOSOLOGY ,ORTHOPEDIC surgery ,ORTHOPEDICS ,RESEARCH funding ,SURGICAL instruments ,TOTAL hip replacement ,VETERANS' hospitals ,COMORBIDITY ,ACQUISITION of data ,PROPORTIONAL hazards models ,RETROSPECTIVE studies ,ANATOMY ,DIAGNOSIS - Abstract
Background and purpose - It is unclear whether metal particles and ions produced by mechanical wear and corrosion of hip prostheses with metal-on-metal (MoM) bearings have systemic adverse effects on health. We compared the risk of heart failure in patients with conventional MoM total hip arthroplasty (THA) and in those with metal-on-polyethylene (MoP) THA. Patients and methods - We conducted a retrospective cohort study using data from the Australian Government Department of Veterans' Affairs health claims database on patients who received conventional THA for osteoarthritis between 2004 and 2012. The MoM THAs were classified into groups: Articular Surface Replacement (ASR) XL Acetabular System, other large-head (LH) (> 32 mm) MoM, and small-head (SH) (≤ 32 mm) MoM. The primary outcome was hospitalization for heart failure after THA. Results - 4,019 patients with no history of heart failure were included (56% women). Men with an ASR XL THA had a higher rate of hospitalization for heart failure than men with MoP THA (hazard ratio (HR) = 3.2, 95% CI: 1.6-6.5). No statistically significant difference in the rate of heart failure was found with the other LH MoM or SH MoM compared to MoP in men. There was no statistically significant difference in heart failure rate between exposure groups in women. Interpretation - An association between ASR XL and hospitalization for heart failure was found in men. While causality between ASR XL and heart failure could not be established in this study, it highlights an urgent need for further studies to investigate the possibility of systemic effects associated with MoM THA. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
19. The extent of medication errors and adverse drug reactions throughout the patient journey in acute care in Australia.
- Author
-
Roughead, Elizabeth E., Semple, Susan J., and Rosenfeld, Ellie
- Subjects
- *
CRITICAL care medicine , *DATABASES , *DRUG side effects , *HEALTH facility administration , *MEDICATION errors , *SAFETY , *SYSTEMATIC reviews - Abstract
Aim: To provide an estimate of the numbers of medication errors and adverse drug reactions that occur along a person's journey through their hospital stay in Australia. Methods: A search of databases and online resources was undertaken to identify published literature on medication safety in the acute care setting in Australia from 2008 to 2013. Data on the rates of adverse drug reactions and medication errors associated with hospitalization was extracted from the published studies. This evidence was synthesized with evidence from previous reviews of medication safety in the acute care setting in Australia conducted in 2002 and 2008. Results: Findings from the Australian literature across the two previous reviews of medication safety and the present review indicate the proportion of all hospital admissions that are medication-related is between 2 and 3%. Studies assessing medication errors on admission to hospital suggest there may be an overall rate of two errors for every three patients at the time of admission to hospital. Large studies examining the rates of prescribing errors in major Australian teaching hospitals give insight into the rates of prescription error and suggest that prescription error rates of up to one error per patient occur in the hospital system. The best available evidence from more recent research suggests that errors (excluding errors of timing) occur in around 9% of medication administrations in hospital. At hospital discharge, errors in medication documentation in discharge summaries may occur at a rate of up to two errors per patient. Conclusions: Medication safety in the various stages of the patient journey through acute care in Australia continues to be a significant problem. However, the extent of medication-related problems in acute care needs to be interpreted within the context of increasingly complex health care. There are an estimated 230 000 medication-related hospital admissions occurring per year. This suggests an annual cost of medication-related admissions of AU$1.2 billion. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
20. Comparing co-morbidities in total joint arthroplasty patients using the RxRisk-V, Elixhauser, and Charlson Measures: a cross-sectional evaluation.
- Author
-
Inacio, Maria C. S., Pratt, Nicole L., Roughead, Elizabeth E., and Graves, Stephen E.
- Subjects
ARTHROPLASTY ,JOINT surgery ,INPATIENT care ,ARTHRODESIS ,MEDICAL care ,PATIENTS ,DATABASES ,INFORMATION storage & retrieval systems ,MEDICAL databases ,MEDICAL records ,TOTAL hip replacement ,TOTAL knee replacement ,COMORBIDITY ,CROSS-sectional method - Abstract
Background: Joint arthroplasty patients have a high prevalence of co-morbidities and this impacts their surgical outcomes. There are different ways to ascertain co-morbidities and appropriate measurement is necessary. The purpose of this study was to: (1) describe the prevalence of co-morbidities in a cohort of total hip arthroplasty (THA) and knee arthroplasty (TKA) patients using two diagnoses-based measures (Charlson and Elixhauser) and one prescription-based measure (RxRisk-V); (2) compare the agreement of co-morbidities amongst the measures.Methods: A cross-sectional study of Australian veterans undergoing THAs (n = 11,848) and TKAs (n = 18,972) between 2001 and 2012 was conducted. Seventeen co-morbidities were identified using the Charlson, 30 using the Elixhauser, and 42 using the RxRisk-V measure. Agreement between co-morbidities was calculated using Kappa (κ) statistics.Results: Combining measures, 64 conditions were identified, of these 28 were only identified using the RxRisk-V, 11 using the Elixhauser, and 2 using the Charlson. The most prevalent conditions was pain treated with anti-inflammatories (58.7% THAs, 55.9% TKAs), pain treated with narcotics (55.0% THAs, 50.9% TKAs), hypertension (56.0% THAs and TKAs), and anticoagulation disorders (53.0% THAs, 48.6% TKAs). Diabetes was the only condition with substantial agreement (all κ > 0.6) amongst all measures. When comparing the diagnoses based algorithms, agreement was high for overlapping conditions (all κ > 0.71).Conclusions: Different measures identified different co-morbidities, provided different estimates for the same co-morbidity, and had different levels of agreement for common co-morbidities. This highlights the importance of understanding co-morbidity measures and using them appropriately in studies and case-mix adjustments analyses. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
21. Predictive performance of four frailty measures in an older Australian population.
- Author
-
WIDAGDO, IMAINA S., PRATT, NICOLE, RUSSELL, MARY, and ROUGHEAD, ELIZABETH E.
- Subjects
COMPARATIVE studies ,CONFIDENCE intervals ,FRAIL elderly ,RESEARCH funding ,STATISTICS ,DATA analysis ,PREDICTIVE tests ,RETROSPECTIVE studies ,RECEIVER operating characteristic curves ,DATA analysis software ,DESCRIPTIVE statistics ,ODDS ratio - Abstract
Background: there are several different frailty measures available for identifying the frail elderly. However, their predictive performance in an Australian population has not been examined. Objective: to examine the predictive performance of four internationally validated frailty measures in an older Australian population. Methods: a retrospective study in the Australian Longitudinal Study of Ageing (ALSA) with 2,087 participants. Frailty was measured at baseline using frailty phenotype (FP), simplified frailty phenotype (SFP), frailty index (FI) and prognostic frailty score (PFS). Odds ratios (OR) were calculated to measure the association between frailty and outcomes at Wave 3 including mortality, hospitalisation, nursing home admission, fall and a combination of all outcomes. Predictive performance was measured by assessing sensitivity, specificity, positive and negative predictive values (PPVand NPV) and likelihood ratio (LR). Area under the curve (AUC) of dichotomised and the multilevel or continuous model of the measures was examined. Results: prevalence of frailty varied from 2% up to 49% between the measures. Frailty was significantly associated with an increased risk of any outcome, OR (95% confidence interval) for FP: 1.9 (1.4-2.8), SFP: 3.6 (1.5-8.8), FI: 3.4 (2.7-4.3) and PFS: 2.3 (1.8-2.8). PFS had high sensitivity across all outcomes (sensitivity: 55.2-77.1%). The PPV for any outcome was highest for SFP and FI (70.8 and 69.7%, respectively). Only FI had acceptable accuracy in predicting outcomes, AUC: 0.59-0.70. Conclusions: being identified as frail by any of the four measures was associated with an increased risk of outcomes; however, their predictive accuracy varied. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
22. Multiple Anticholinergic Medication Use and Risk of Hospital Admission for Confusion or Dementia.
- Author
-
Kalisch Ellett, Lisa M., Pratt, Nicole L., Ramsay, Emmae N., Barratt, John D., and Roughead, Elizabeth E.
- Subjects
ELDER care ,COGNITION disorders ,CONFIDENCE intervals ,DEMENTIA ,HOSPITAL care ,LONGITUDINAL method ,VETERANS ,PARASYMPATHOMIMETIC agents ,RESEARCH funding ,RISK assessment ,RETROSPECTIVE studies ,POLYPHARMACY ,DATA analysis software ,DESCRIPTIVE statistics - Abstract
Objectives To identify the association between use of multiple anticholinergic medications and risk of hospitalization for confusion or dementia. Design Retrospective cohort study conducted over 2 years between July 2010 and June 2012, using administrative claims data from the Australian Department of Veterans' Affairs. Setting Australia. Participants Australian veterans dispensed at least one moderately or highly anticholinergic medication in the year before study start. Measurements Cumulative anticholinergic use on each day of the study period was determined. The association between hospitalization for confusion or dementia and number of anticholinergic medications used at the time of admission was compared against times during which participants were not taking anticholinergic medications. Sensitivity analyses were undertaken limiting the outcome to admissions for acute confusion and excluding individuals taking antipsychotics. Results Adjusted results showed a significantly greater risk of hospitalization for confusion or dementia when individuals were taking two or more anticholinergic medications. The adjusted incident rate ratios ( IRRs) were 2.58 (95% confidence interval ( CI) = 1.91-3.48) for those taking two anticholinergics and 3.87 (95% CI = 1.83-8.21) for those taking three or more. Sensitivity analyses in which participants taking antipsychotic medications were excluded and the outcome was limited to acute confusion also found similar risks for those taking two ( IRR 1.82, 95% CI = 1.18-2.80) and three or more ( IRR = 3.98 95% CI = 1.50-10.58) anticholinergic medications. Conclusion Taking more anticholinergic medications is associated with greater risk of hospitalization for confusion or dementia. Strategies to reduce anticholinergic medication burden are likely to translate into significant health benefits. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
23. Risk of Medication-Associated Initiation of Oxybutynin in Elderly Men and Women.
- Author
-
Kalisch Ellett, Lisa M., Pratt, Nicole L., Barratt, John D., Rowett, Debra, and Roughead, Elizabeth E.
- Subjects
DRUG dosage ,URINARY incontinence diagnosis ,CONFIDENCE intervals ,DRUGS ,RESEARCH funding ,URINARY incontinence ,OXYBUTYNIN (Drug) ,DATA analysis software ,DESCRIPTIVE statistics ,OLD age - Abstract
Objectives To determine whether there is greater risk of initiation of oxybutynin to treat urinary incontinence ( UI) after initiation of medicines reported to be associated with UI. Design Prescription sequence symmetry analysis ( PSSA). Setting Administrative claims data from the Australian Government Department of Veterans' Affairs. Participants Individuals who initiated oxybutynin and a medicine reported to be associated with UI in a 12-month period. Measurements Between January 1, 2001, and December 31, 2011, the distribution of incident dispensing of medicines reported to be associated with UI (prazosin, diuretics, calcium channel blockers ( CCBs), angiotensin-converting enzyme inhibitors ( ACEIs), angiotensin receptor blockers ( ARBs), hormone replacement therapy ( HRT), opioid analgesics, anticonvulsants, levodopa, antipsychotics, sedatives, selective serotonin reuptake inhibitors ( SSRIs), venlafaxine, anticholinesterases) was assessed before and after incident dispensing of oxybutynin (to treat UI). Crude and adjusted sequence ratios ( ASRs) with 95% confidence intervals ( CIs) were calculated. Results Significant associations between initiation of CCBs, ACEIs, ARBs, and hypnotic-sedatives and subsequent initiation of oxybutynin were found. ASRs ranged from 1.28 (95% CI = 1.19-1.39) for ACEIs to 1.59 (95% CI = 1.29-1.96) for verapamil. In women, there was greater risk of initiation of oxybutynin after prazosin ( ASR = 1.84, 95% CI = 1.29-2.63) and HRT ( ASR = 1.54, 95% CI = 1.42-1.67) initiation. PSSA showed no significant association with initiation of opioids, anticonvulsants, levodopa, SSRIs, venlafaxine, or anticholinesterases and subsequent initiation of oxybutynin. Conclusion This study highlights the potential for initiation of commonly used medicines to be associated with subsequent initiation of oxybutynin to treat UI. Greater awareness of the potential for medicines to contribute to UI is required. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
24. Medicine Use among Older Australians Before and After Hip Fracture.
- Author
-
Leach, Michael J., Pratt, Nicole L., and Roughead, Elizabeth e.
- Subjects
ANALGESICS ,ANTIDEPRESSANTS ,ANTIPSYCHOTIC agents ,BENZODIAZEPINES ,DRUG therapy ,ACCIDENTAL falls ,BONE fractures ,HIP joint injuries ,VETERANS ,NARCOTICS ,RESEARCH funding ,TRANQUILIZING drugs ,DATA analysis ,DATA analysis software ,DESCRIPTIVE statistics ,OLD age - Abstract
Background: Hip fracture impacts on quality of life and may lead to premature death. In Australia, the extent of use of medicines that increase risk of falls or hip fracture in at-risk older people is not known. Aim: To determine the use of medicines associated with falls or hip fracture before hip fracture and whether medicine use changed after hip fracture. Method: Data from the Australian Department of Veterans' Affairs healthcare claims database were used. The cohort included patients aged > 65 years who were hospitalised for hip fracture in 2009. Percentages of patients using medicines associated with falls or hip fracture were calculated in the 6 weeks before hospitalisation for hip fracture. McNemar's test was used to assess changes in medicines used before admission and after discharge from hospital. Results: 2235 patients with a median age of 87 years had hip fractures in 2009. At least 1 medicine that increases risk of falls or hip fracture was used by 84% of patients before admission. Of the drug classes that increase risk of falls or hip fracture, the 4 most commonly dispensed before admission were antihypertensives (63%), antidepressants (29%), benzodiazepines (26%) and opioids (19%). After discharge, the use of antipsychotics (p < 0.0001), opioids (p < 0.0001), benzodiazepines (p = 0.0009) and antidepressants (p = 0.01) increased significantly. Conclusion: Most older patients used at least 1 medicine that increases the risk of falls or hip fracture before and after hip fracture. Antipsychotic, opioid, benzodiazepine and antidepressant use increased significantly after hospital discharge. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
25. Bridging evidence-practice gaps: improving use of medicines in elderly Australian veterans.
- Author
-
Roughead, Elizabeth E., Kalisch Ellett, Lisa M., Ramsay, Emmae N., Pratt, Nicole L., Barratt, John D., LeBlanc, Vanessa T., Ryan, Philip, Peck, Robert, Killer, Graeme, and Gilbert, Andrew L.
- Subjects
- *
HEALTH promotion , *MEDICAL care of veterans , *HEALTH services administration , *REGRESSION analysis , *NONSTEROIDAL anti-inflammatory agents , *ANTIPSYCHOTIC agents ,AUSTRALIA. Dept. of Veterans' Affairs - Abstract
Background The Australian Government Department of Veterans' Affairs (DVA) funds an ongoing health promotion based program to improve use of medicines and related health services, which implements interventions that include audit and feedback in the form of patient-specific feedback generated from administrative claims records. We aimed to determine changes in medicine use as a result of the program. Methods The program provides targeted patient-specific feedback to medical practitioners. The feedback is supported with educational material developed by a clinical panel, subject to peer review and overseen by a national editorial committee. Veterans who meet target criteria also receive educational brochures. The program is supported by a national call centre and ongoing national consultation. Segmented regression analyses (interrupted time series) were undertaken to assess changes in medication use in targeted veterans pre and post each intervention. Results 12 interventions were included; three to increase medicine use, seven which aimed to reduce use, and two which had combination of messages to change use. All programs that aimed to increase medicine use were effective, with relative effect sizes at the time of the intervention ranging from 1% to 8%. Mixed results were seen with programs aiming to reduce inappropriate medicine use. Highly specific programs were effective, with relative effect sizes at the time of the intervention of 10% decline in use of NSAIDs in high risk groups and 14% decline in use of antipsychotics in dementia. Interventions targeting combinations of medicines, including medicine interactions and potentially inappropriate medicines in the elderly did not change practice significantly. Interventions with combinations of messages targeting multiple components of practice had an impact on one component, but not all components targeted. Conclusions The Veterans' MATES program showed positive practice change over time, with interventions increasing use of appropriate medicines where under-use was evident and reduced use of inappropriate medicines when single medicines were targeted. Combinations of messages were less effective, suggesting specific messages focusing on single medicines are required to maximise effect. The program provides a model that could be replicated in other settings. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
26. Impact of cost of medicines for chronic conditions on low income households in Australia.
- Author
-
Kemp, Anna, Preen, David B., Glover, John, Semmens, James, and Roughead, Elizabeth E.
- Subjects
DRUGS & economics ,PUBLIC welfare ,SURVEYS ,CHI-squared test ,CHRONIC diseases ,EMPLOYMENT ,INCOME ,MEDICAL care costs ,PENSIONS ,RESEARCH funding ,SOCIAL security ,T-test (Statistics) ,U-statistics ,COMORBIDITY ,COST analysis ,RESIDENTIAL patterns ,SECONDARY analysis ,DESCRIPTIVE statistics ,STATISTICS - Abstract
Objectives: To determine the cost of medicines for selected chronic illnesses and the proportion of discretionary income this would potentially displace for households with different pharmaceutical subsidy entitlements and incomes. Methods: We analysed household income and expenditure data for 9,774 households participating in two Australian surveys in 2009-10. The amount of 'discretionary' income available to households after basic living and health care expenditure was modelled for households with high pharmaceutical subsidies: pensioner and non-pensioner concessional (social security entitlements); and households with general pharmaceutical subsidies and low, middle or high incomes. We calculated the proportion of discretionary income that would be needed for medicines if one household member had diabetes or acute coronary syndrome, or if one member also had two co-existing illnesses (gastro-oesophageal reflux disease and depression, or asthma and osteoarthritis). Results: Pensioner and low income households had little discretionary income after basic living and health care expenditure (AUD$92 and $164/week, respectively). Medicines for the specified illnesses ranged from $11-$42/month for high subsidy households and $34-$186/month for low subsidy households. Costs reduced substantially once patients reached the annual pharmaceutical cap (safety net), prior to which medicine costs would displace the equivalent of 1%-10% of discretionary income for most household types. However, low income households would have to forego the equivalent of between 5%-26% of their discretionary income for between 7 and 9 months of the year before receiving additional subsidies. Conclusions: Prescription medicines for chronic conditions pose a substantial financial burden to many households, particularly those with low incomes and general pharmaceutical subsidies. Policies are needed to minimize the cost burden of prescription medicines, particularly for low-income working households. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
27. COX-2 Inhibitor and Non-Selective NSAID Use in Those at Increased Risk of NSAID-Related Adverse Events.
- Author
-
Gadzhanova, Svetla, Ilomäki, Jenni, and Roughead, Elizabeth E.
- Subjects
NONSTEROIDAL anti-inflammatory agents ,POISSON distribution ,RESEARCH funding ,CYCLOOXYGENASE 2 ,RETROSPECTIVE studies ,DATA analysis software ,OLD age - Abstract
Background Adverse events related to analgesic use represent a challenge for optimizing treatment of pain in older people. Objective The aim of this study was to determine whether non-selective non-steroidal anti-inflammatory drug (NS-NSAID) and cyclo-oxygenase (COX)-2 inhibitor use is appropriately targeted in those with a prior history of gastrointestinal (GI) events, myocardial infarction (MI) or stroke. Methods A retrospective study of pharmacy claims data from the Australian Government Department of Veterans' Affairs was conducted, involving 288,912 veterans aged 55 years and over. Analgesic utilization from 2007 to 2009 was assessed. Three risk cohorts (veterans with prior hospitalization for GI bleed, MI or stroke) and a low-risk cohort were identified. Poisson regression was applied to test for a linear trend over the study period. Results The prevalence of analgesics dispensed in the overall study population was approximately 34 % between 2007 and 2009. COX-2 inhibitors were more widely dispensed than NS-NSAIDs in all those at risk of NSAIDrelated adverse events. At the end of 2009, the ratio was 5.1 % to 2.5 % in the GI cohort, 3.6 % to 3.2 % in the MI cohort and 3.6 % to 2.6 % in the stroke cohort. Conclusions Although COX-2 inhibitors appeared to be preferred over NS-NSAIDs in those with a prior history of GI events, 2.5 % of patients were still using an NS-NSAID at the end of the study period. Consistent with treatment guidelines, in most of these cases, these drugs were co-dispensed with proton pump inhibitors. COX-2 inhibitors were used at slightly higher rates than NS-NSAIDs in those with a prior history of MI or stroke, which is not consistent with guidelines recommending NS-NSAID use. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
28. Prevalence of preventable medication-related hospitalizations in Australia: an opportunity to reduce harm.
- Author
-
Kalisch, Lisa M., Caughey, Gillian E., Barratt, John D., Ramsay, Emmae N., Killer, Graeme, Gilbert, Andrew L., and Roughead, Elizabeth E.
- Subjects
DISEASE prevalence ,DRUG side effects ,ADVERSE health care events ,HOSPITAL care ,COHORT analysis ,OBSTRUCTIVE lung disease treatment ,MENTAL depression ,THERAPEUTICS ,BRAIN disease treatment ,CEREBROVASCULAR disease - Abstract
Objective To identify the prevalence of potentially preventable medication-related hospitalizations amongst elderly Australian veterans by applying clinical indicators to administrative claims data. Design and Setting Retrospective cohort study in the Australian veteran population from 1 January 2004 to 31 December 2008. Participants A total of 109 044 veterans with one or more hospitalizations defined by the medication-related clinical indicator set, during the 5-year study period. Main Outcome Measure The prevalence of potentially preventable medication-related hospitalizations as a proportion of all hospitalizations defined by the clinical indicator set. Results During the 5-year study period, there were a total of 1 630 008 hospital admissions of which 216 527 (13.3%) were for conditions defined by the medication-related clinical indicator set for 109 044 veterans. The overall proportion of potentially preventable medication-related hospitalizations was 20.3% (n= 43 963). Of the 109 044 veterans included in the study, 28 044 (25.7%) had at least one potentially preventable medication-related hospitalization and 7245 (6.6%) veterans had two or more potentially preventable admissions. Conditions with both a high prevalence of hospitalization and preventability included asthma/chronic obstructive pulmonary disorder, depression and thromboembolic cerebrovascular event (23.3, 18.5 and 18.3%, respectively, were potentially preventable). Other hospitalizations that were less common but had a high level of preventability (at least 20%) included hip fracture, impaction, renal failure, acute confusion, bipolar disorder and hyperkalaemia. Conclusions The results of this study highlight those conditions where hospitalizations could potentially be avoided through improved medication management. Strategies to increase the awareness, identification and resolution of these medication-related problems contributing to these hospitalizations are required in Australia. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
29. Prescriber Feedback to Improve Quality Use of Medicines among Older People: the Veterans' MATES Program.
- Author
-
Bell, J. Simon, Kalisch, Lisa M., Ramsay, Emmae N., Pratt, Nicole L., Barratt, John D., LeBlanc, Tammy, Roughead, Elizabeth E., and Gilbert, Andrew L.
- Subjects
GENERAL practitioners ,QUALITY assurance ,MEDICAL protocols ,ATTITUDE (Psychology) ,CONCEPTUAL structures ,DRUG utilization ,VETERANS ,MEDICAL personnel ,PATIENT education ,PHARMACISTS ,RESEARCH funding ,EVALUATION of human services programs ,EDUCATION - Abstract
Since 2004, the Department of Veterans' Affairs (DVA) has funded the Veterans' Medicines Advice and Therapeutics Education Services (MATES) program. The main intervention of the program is quarterly targeted patient-specific prescriber feedback. The feedback comprises a list of relevant medications dispensed to each patient and notes about potential medicationrelated problems specific to the intervention. Supportive educational material is provided to assist general practitioners (GPs) resolve these medication-related problems. Veterans identified in the GP mailing are sent an educational brochure highlighting medication issues and encouraging them to speak with their doctor. To enable pharmacists to support this practice change, educational material is also provided to all pharmacies and accredited pharmacists. The most recent of the 28 interventions implemented to date have addressed osteoporosis, opioid-induced constipation and urinary incontinence. Overall, program materials have been mailed to 249 454 veterans, 34 527 GPs and around 8000 pharmacies and accredited pharmacists. Evaluation has demonstrated a doubling of home medicines review (HMR) rates in the veteran population. Analyses of the DVA data have reported a 45% reduction in hospitalisation for heart failure following HMR among veterans with heart failure (adjusted hazard ratio [HR] 0.6; 95% confidence interval [CI] 0.4-0.8), and a 79% reduction in hospitalisation for haemorrhage (HR 0.2; 95%CI 0.05-0.9) 2 to 6 months after an HMR in veterans dispensed warfarin. Veterans' MATES has resulted in clinically significant improvements in medication and health service use. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
30. Improvement in metformin and insulin utilisation in the Australian veteran population associated with quality use of medicines intervention programs.
- Author
-
Gadzhanova, Svetla, Roughead, Elizabeth E., Loukas, Katrina, and Vajda, Jacqualine
- Subjects
TREATMENT of diabetes ,DRUG therapy ,TRENDS ,METFORMIN ,INSULIN - Abstract
The article provides information on a study which analyzed the impact of 2001 and 2005 National Prescribing Service (NPS) quality use of medicines (QUM) diabetes programs on the trends in metformin and insulin use among diabetes veterans in Australia. The utilization of change-in-level and change-in-trend terms to determine the impact of both programs on the use of metformin and insulin concurrent with oral hypoglycaemics is highlighted. It notes that over 55 percent of the diabetes population received metformin alone or in combination.
- Published
- 2011
- Full Text
- View/download PDF
31. Influence of Comorbidities on Therapeutic Progression of Diabetes Treatment in Australian Veterans: A Cohort Study.
- Author
-
Vitry, Agnes I., Roughead, Elizabeth E., Preiss, Adrian K., Ryan, Philip, Ramsay, Emmae N., Gilbert, Andrew L., Caughey, Gillian E., Shakib, Sepehr, Esterman, Adrian, Ying Zhang, and McDermott, Robyn A.
- Subjects
- *
TREATMENT of diabetes , *THERAPEUTICS , *HYPOGLYCEMIC agents , *METFORMIN , *SULFONYLUREAS , *HOSPITAL care , *COMORBIDITY , *ENDOCRINOLOGY ,DISEASES in veterans - Abstract
Background: This study assessed whether the number of comorbid conditions unrelated to diabetes was associated with a delay in therapeutic progression of diabetes treatment in Australian veterans. Methodology/Principal Findings: A retrospective cohort study was undertaken using data from the Australian Department of Veterans' Affairs (DVA) claims database between July 2000 and June 2008. The study included new users of metformin or sulfonylurea medicines. The outcome was the time to addition or switch to another antidiabetic treatment. The total number of comorbid conditions unrelated to diabetes was identified using the pharmaceutical-based comorbidity index, Rx-Risk-V. Competing risk regression analyses were conducted, with adjustments for a number of covariates that included age, gender, residential status, use of endocrinology service, number of hospitalisation episodes and adherence to diabetes medicines. Overall, 20134 veterans were included in the study. At one year, 23.5% of patients with diabetes had a second medicine added or had switched to another medicine, with 41.4% progressing by 4 years. The number of unrelated comorbidities was significantly associated with the time to addition of an antidiabetic medicine or switch to insulin (subhazard ratio [SHR] 0.87 [95% CI 0.84-0.91], P,0.001). Depression, cancer, chronic obstructive pulmonary disease, dementia, and Parkinson's disease were individually associated with a decreased likelihood of therapeutic progression. Age, residential status, number of hospitalisations and adherence to anti-diabetic medicines delayed therapeutic progression. Conclusions/Significance: Increasing numbers of unrelated conditions decreased the likelihood of therapeutic progression in veterans with diabetes. These results have implications for the development of quality measures, clinical guidelines and the construction of models of care for management of diabetes in elderly people with comorbidities. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
32. Prevalence of potentially hazardous drug interactions amongst Australian veterans.
- Author
-
Roughead, Elizabeth E., Kalisch, Lisa M., Barratt, John D., and Gilbert, Andrew L.
- Subjects
- *
DRUG side effects , *HOSPITAL admission & discharge , *DRUG interactions , *POLYPHARMACY , *COUMARINS - Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Up to 21% of adverse drug event related hospital admissions are due to drug interactions. Clinical significance of drug interactions varies. • Studies which only identified drug interactions of potentially major clinical significance found lower prevalence, of between 2 and 16%. • Prevalence of drug interactions defined ‘potentially hazardous’ has had limited study, with no publications identified for the Australian population. WHAT THIS STUDY ADDS • In the study population of 287 074, 1.5% of subjects were dispensed potentially hazardous interacting drug pairs. • However, limited to populations on specific medicines, it was found that for patients dispensed verapamil, methotrexate, amiodarone, lithium, warfarin, cyclosporin and itraconazole, potentially hazardous interactions occurred at a rate greater than 5%. • These patients should be the focus of medication review programmes to avoid potentially serious adverse drug events. BACKGROUND Up to 21% of adverse drug event-related hospital admissions are due to drug interactions. Clinical significance of drug interactions varies, and drug interactions defined ‘potentially hazardous’ are more likely to contribute to morbidity and mortality. AIM The aim of this study was to assess the prevalence of potentially hazardous drug interactions in an elderly Australian veteran population. METHODS This study assessed the prevalence of potentially hazardous drug interactions, where hazardous was defined in three or more international drug interaction references, using Repatriation Pharmaceutical Benefits Scheme pharmacy claims data. Analysis was limited to patients who received regular concurrent dispensings of potentially hazardous interacting medicines. RESULTS Of the 287 074 subjects included in the study, 1.5% were dispensed potentially hazardous interacting drug pairs. For patients dispensed cyclosporin, concomitant use of a statin was common (47%); as was statin use with those dispensed itraconazole (31%). Of those dispensed methotrexate, 24% also received a non-steroidal anti-inflammatory drug; of those on lithium, 18% also received an ACE inhibitor or angiotensin 2 receptor blocker; of those on warfarin, 7.2% and 5.9% were co-dispensed an non-steroidal anti-inflammatory drugs or antiplatelets respectively; for those on verapamil, 5.3% were co-dispensed a beta-blocker, while for those on amiodarone 6.2% were co-dispensed digoxin. CONCLUSIONS Overall prevalence of potentially serious drug interactions appears to be low in the Australian veteran population. However, patients taking cyclosporine, itraconazole, methotrexate, lithium, warfarin, verapamil and amiodarone appear to be most at risk and their medicine use should be regularly reviewed to prevent potentially hazardous drug interactions. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
33. Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia.
- Author
-
Othman, Noordin, Vitry, Agnes I., Roughead, Elizabeth E., Ismail, Shaiful B., and Omar, Khairani
- Subjects
DRUG side effects ,MEDICAL research ,PHARMACODYNAMICS ,DRUG interactions - Abstract
Background: Pharmaceutical representatives provide medicines information on their promoted products to doctors. However, studies have shown that the quality of this information is often low. No study has assessed the medicines information provided by pharmaceutical representatives to doctors in Malaysia and no recent evidence in Australia is present. We aimed to compare the provision of medicines information by pharmaceutical representatives to doctors in Australia and Malaysia. Methods: Following a pharmaceutical representative's visit, general practitioners in Australia and Malaysia who had agreed to participate, were asked to fill out a questionnaire on the main product and claims discussed during the encounter. The questionnaire focused on provision of product information including indications, adverse effects, precautions, contraindications and the provision of information on the Pharmaceutical Benefit Scheme (PBS) listings and restrictions (in Australia only). Descriptive statistics were produced. Chi-square analysis and clustered linear regression were used to assess differences in Australia and Malaysia. Results: Significantly more approved product information sheets were provided in Malaysia (78%) than in Australia (53%) (P < 0.001). In both countries, general practitioners reported that indications (Australia, 90%, Malaysia, 93%) and dosages (Australia, 76%, Malaysia, 82%) were frequently provided by pharmaceutical representatives. Contraindications, precautions, drug interactions and adverse effects were often omitted in the presentations (range 25% - 41%). General practitioners in Australia and Malaysia indicated that in more than 90% of presentations, pharmaceutical representatives partly or fully answered their questions on contraindications, precautions, drug interactions and adverse effects. More general practitioners in Malaysia (85%) than in Australia (60%) reported that pharmaceutical representatives should have mentioned contraindications, precautions for use, drug interaction or adverse effects spontaneously (P < 0.001). In 48% of the Australian presentations, general practitioners reported the pharmaceutical representatives failed to mention information on PBS listings to general practitioners. Conclusions: Information on indications and dosages were usually provided by pharmaceutical representatives in Australia and Malaysia. However, risk and harmful effects of medicines were often missing in their presentations. Effective control of medicines information provided by pharmaceutical representatives is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
34. Quality of claims, references and the presentation of risk results in medical journal advertising: a comparative study in Australia, Malaysia and the United States.
- Author
-
Othman, Noordin, Vitry, Agnes I., and Roughead, Elizabeth E.
- Subjects
MEDICAL research ,PHYSICIANS ,PHARMACEUTICAL industry ,MEDICAL literature ,ADVERTISING of periodicals - Abstract
Background: Journal advertising is used by pharmaceutical companies to disseminate medicine information to doctors. The quality of claims, references and the presentation of risk results in Australia and the US has been questioned in several studies. No recent evidence is available on the quality of claims, references and the presentation of risk results in journal advertising in Australia and the US and no Malaysian data have been published. The aim of this study was to compare the quality of claims, references and the presentation of risk results in journal advertising in these three countries.Methods: A consecutive sample of 85 unique advertisements from each country was selected from journal advertising published between January 2004 to December 2006. Claims, references and the presentation of risk results in medical journal advertising were compared between the three countries.Results: Less than one-third of the claims were unambiguous claims (Australia, 30%, Malaysia 17%, US, 23%). In Malaysia significantly less unambiguous claims were provided than in Australia and the US (P < 0.001). However, the unambiguous claims were supported by more references than other claims (80%). Most evidence was obtained from at least one randomized controlled trial, a systematic review or meta-analysis (Australia, 84%, Malaysia, 81%, US, 76%) with journal articles being the most commonly cited references in all countries. Data on file were significantly more likely to be cited in the US (17%) than in Australia (2%) and Malaysia (4%) (P < 0.001). Advertisements that provided quantitative information reported risk results exclusively as a relative risk reduction.Conclusions: The majority of claims were vague suggesting poor quality of claims in journal advertising in these three countries. Evidence from a randomized controlled trial, systematic review or meta- analysis was commonly cited to support claims. However, the more frequent use of data that have not been published and independently reviewed in the US compared to Australia and Malaysia raises questions on the quality of references in the US. The use of relative rather than absolute benefits may overemphasize the benefit of medicines which may leave doctors susceptible to misinterpreting information. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
35. The Effectiveness of Collaborative Medicine Reviews in Delaying Time to Next Hospitalization for Patients With Heart Failure in the Practice Setting Results of a Cohort Study.
- Author
-
Roughead, Elizabeth E., Barratt, John D., Ramsay, Emrnae, Pratt, Nicole, Ryan, Philip, Peck, Robert, Killer, Graeme, and Gilbert, Andrew L.
- Subjects
HEART failure patients ,EVALUATION of medical care ,HOSPITAL care of older people ,HEART failure clinics ,SURVIVAL analysis (Biometry) ,MEDICAL care of veterans ,WIDOWS ,MEDICAL care - Abstract
The article presents a study which aimed to find out if collaborative medication reviews can improve results for patients with heart failure. The study specifically looked into the impact of the provision of a Home Medicines Review (HMR) for Australian war veterans and widows with heart failure on the time to next hospitalization for the disorder. Kaplan-Meier analyses and Cox proportional hazard models were used in comparing the effects on patients who received the HMR with those who did not.
- Published
- 2009
- Full Text
- View/download PDF
36. Implementation and Evaluation of a Digitally Enabled Precision Public Health Intervention to Reduce Inappropriate Gabapentinoid Prescription: Cluster Randomized Controlled Trial.
- Author
-
Andrade, Andre Q, Calabretto, Jean-Pierre, Pratt, Nicole L, Kalisch-Ellett, Lisa M, Kassie, Gizat M, LeBlanc, Vanessa T, Ramsay, Emmae, and Roughead, Elizabeth E
- Subjects
RESEARCH ,RESEARCH methodology ,PUBLIC health ,EVALUATION research ,INAPPROPRIATE prescribing (Medicine) ,COMPARATIVE studies ,RANDOMIZED controlled trials ,QUESTIONNAIRES - Abstract
Background: Digital technologies can enable rapid targeted delivery of audit and feedback interventions at scale. Few studies have evaluated how mode of delivery affects clinical professional behavior change and none have assessed the feasibility of such an initiative at a national scale.Objective: The aim of this study was to develop and evaluate the effect of audit and feedback by digital versus postal (letter) mode of delivery on primary care physician behavior.Methods: This study was developed as part of the Veterans' Medicines Advice and Therapeutics Education Services (MATES) program, an intervention funded by the Australian Government Department of Veterans' Affairs that provides targeted education and patient-specific audit with feedback to Australian general practitioners, as well as educational material to veterans and other health professionals. We performed a cluster randomized controlled trial of a multifaceted intervention to reduce inappropriate gabapentinoid prescription, comparing digital and postal mode of delivery. All veteran patients targeted also received an educational intervention (postal delivery). Efficacy was measured using a linear mixed-effects model as the average number of gabapentinoid prescriptions standardized by defined daily dose (individual level), and number of veterans visiting a psychologist in the 6 and 12 months following the intervention.Results: The trial involved 2552 general practitioners in Australia and took place in March 2020. Both intervention groups had a significant reduction in total gabapentinoid prescription by the end of the study period (digital: mean reduction of 11.2%, P=.004; postal: mean reduction of 11.2%, P=.001). We found no difference between digital and postal mode of delivery in reduction of gabapentinoid prescriptions at 12 months (digital: -0.058, postal: -0.058, P=.98). Digital delivery increased initiations to psychologists at 12 months (digital: 3.8%, postal: 2.0%, P=.02).Conclusions: Our digitally delivered professional behavior change intervention was feasible, had comparable effectiveness to the postal intervention with regard to changes in medicine use, and had increased effectiveness with regard to referrals to a psychologist. Given the logistical benefits of digital delivery in nationwide programs, the results encourage exploration of this mode in future interventions. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
37. Prevalence of comorbidity of chronic diseases in Australia.
- Author
-
Caughey, Gillian E., Vitry, Agnes I., Gilbert, Andrew L., and Roughead, Elizabeth E.
- Subjects
COMORBIDITY ,CHRONIC diseases ,OLDER people ,MEDICAL care - Abstract
Background: The prevalence of comorbidity is high, with 80% of the elderly population having three or more chronic conditions. Comorbidity is associated with a decline in many health outcomes and increases in mortality and use of health care resources. The aim of this study was to identify, review and summarise studies reporting the prevalence of comorbidity of chronic diseases in Australia. Methods: A systematic review of Australian studies (1996 - May 2007) was conducted. The review focused specifically on the chronic diseases included as national health priorities; arthritis, asthma, cancer, cardiovascular disease (CVD), diabetes mellitus and mental health problems. Results: A total of twenty five studies met our inclusion criteria. Over half of the elderly patients with arthritis also had hypertension, 20% had CVD, 14% diabetes and 12% mental health problem. Over 60% of patients with asthma reported arthritis as a comorbidity, 20% also had CVD and 16% diabetes. Of those with CVD, 60% also had arthritis, 20% diabetes and 10% had asthma or mental health problems. Conclusion: There are comparatively few Australian studies that focused on comorbidity associated with chronic disease. However, they do show high prevalence of comorbidity across national health priority areas. This suggests integration and co-ordination of the national health priority areas is critical. A greater awareness of the importance of managing a patients' overall health status within the context of comorbidity is needed together with, increased research on comorbidity to provide an appropriate scientific basis on which to build evidence based care guidelines for these multimorbid patients. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
38. Prices for Innovative Pharmaceutical Products That Provide Health Gain: A Comparison Between Australia and the United States.
- Author
-
Roughead, Elizabeth E., Lopert, Ruth, and Sansom, Lloyd Norman
- Subjects
- *
DRUG prices , *PHARMACEUTICAL industry , *PRICING , *COMMERCIAL treaties - Abstract
Objectives: Pricing polices used in many countries are often viewed in the United States as a mechanism of price constraint. Support for this contention has arisen from pricing studies which demonstrate that the United States pays higher prices for many pharmaceutical products. No study to date, however, has examined the prices paid for pharmaceuticals that provide significant health gain, which might be expected to be lower where price constraints were operating. This study aimed to examine prices paid by federal government programs and agencies in Australia and the United States for pharmaceutical products that provide significant health gain. Methods: Products identified by the US Food and Drug Administration and the Canadian Patented Medicines Prices Review Board as likely to confer significant health gains between 1999 and 2004 were identified. Australian and USfederal government prices ($US) and US average manufacturer prices (AMP), which do not include discounts or rebates, during the second quarter of 2006 were compared. Results: Of 22 products for which comparisons were possible, Australian prices were higher than the US Federal Supply Schedule (FSS) prices for 14 (64%) products. When compared with AMP, Australian prices were higher for eight of the 22 products. Overall, Australian prices were higher on average by 4.2% when compared with the FSS and lower by 14.4% when compared with the AMP. Conclusion: These results suggest that Australian prices for medicines representing significant advances in therapy are similar to those paid under key US programs despite fundamental differences in policy contexts. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
39. Trends over 5 years in cardiovascular medicine use in Australian veterans with diabetes.
- Author
-
Roughead, Elizabeth E., Pratt, Nicole, and Gilbert, Andrew L.
- Subjects
- *
CARDIOVASCULAR agents , *TREATMENT of diabetes , *ACE inhibitors , *VETERANS , *DRUG monitoring , *DRUG utilization - Abstract
What is already known about this subject • Previous cross-sectional studies have demonstrated underuse of cardiovascular medicines in the population with diabetes. What this study adds • Trends are changing over 5 years with increasing use of medicines affecting the angiotensin–renin system, lipid-lowering medicines and antiplatelets in the Australian veteran population, in line with recommended practice. Aim To determine trends over 5 years in cardiovascular medicine use in the Australian veteran population with diabetes Methods An observational study. All veterans dispensed medicines indicative of diabetes between 2000 and 2005 were identified from the Veterans Affairs pharmacy claims dataset. Concurrent dispensings of angiotensin-converting enzyme inhibitor (ACEI), lipid-lowering medicines and antiplatelets were assessed. Results ACEI/angiotensin II receptor blocker use has risen from 46% to 67% in the veteran population dispensed medicines indicative of diabetes. Lipid-lowering medicines have increased from 33% to 58% and antiplatelets from 28% to 50%. Conclusion The increasing use of cardiovascular medicines in the diabetes population is suggestive of improved treatment practices over time, consistent with guidelines and quality use of medicines initiatives. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
40. Consumer involvement in Quality Use of Medicines (QUM) projects -- lessons from Australia.
- Author
-
Kirkpatrick, Carl MJ, Roughead, Elizabeth E, Monteith, Gregory R, and Tett, Susan E
- Subjects
- *
MEDICAL care research , *HEALTH policy , *POLICY analysis , *CONSUMERS - Abstract
Background: It is essential that knowledge gained through health services research is collated and made available for evaluation, for policy purposes and to enable collaboration between people working in similar areas (capacity building). The Australian Quality Use of Medicine (QUM) on-line, web-based project database, known as the QUMmap, was designed to meet these needs for a specific sub-section of health services research related to improving the use of medicines. Australia's National Strategy for Quality Use of Medicines identifies the primacy of consumers as a major principle for quality use of medicines, and aims to support consumer led research. The aim of this study was to determine how consumers as a group have been represented in QUM projects in Australia. A secondary aim was to investigate how the projects with consumer involvement fit into Australia's QUM policy framework. Method: Using the web-based QUMmap, all projects which claimed consumer involvement were identified and stratified into four categories, projects undertaken by; (a) consumers for consumers, (b) health professionals for consumers, (c) health professionals for health professionals, and (d) other. Projects in the first two categories were then classified according to the policy 'building blocks' considered necessary to achieve QUM. Results: Of the 143 'consumer' projects identified, the majority stated to be 'for consumers' were either actually by health professionals for health professionals (c) or by health professionals for consumers (b) (47% and 40% respectively). Only 12 projects (9%) were directly undertaken by consumers or consumer groups for consumers (a). The majority of the health professionals for consumers (b) projects were directed at the provision of services and interventions, but were not focusing on the education, training or skill development of consumers. Conclusion: Health services research relating to QUM is active in Australia and the projects are collated and searchable on the web-based interactive QUMmap. Healthcare professionals appear to be dominating nominally 'consumer focussed' research, with less than half of these projects actively involving the consumers or directly benefiting consumers. The QUMmap provides a valuable tool for policy analysis and for provision of future directions through identification of QUM initiatives. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
41. Quality Use of Medicines in Aged-Care Facilities in Australia.
- Author
-
Roughead, Elizabeth E., Semple, Susan J., and Gilbert, Andrew L.
- Subjects
- *
ELDER care , *HEALTH of older people , *GERIATRICS , *MEDICAL care - Abstract
Medication-related problems are most commonly reported in elderly patients. It is for this reason that the development of services supporting appropriate medication management in the elderly is paramount; particularly for those living in residential care facilities. In 1991, Australia had very limited services supporting the quality use of medicines for residents of aged-care facilities. Over 11 years, from 1991–2002, the range of services has expanded considerably. Federally funded medication review services are now available, with over 80% of residents provided with the service. Medication advisory committees, in accordance with national practice guidelines, have been established in many facilities to address issues concerning medication management. Fifty percent of Australian’s pharmacies are registered to provide services, with over 10% of the country’s pharmacists accredited to provide the service. National practice guidelines for medication management in aged-care facilities have been incorporated into accreditation standards for aged-care facilities, further integrating activity into the wider health system. The environment was created for these activities through the formation of the Pharmaceutical Health and Rational Use of Medicines (PHARM) Committee, an expert advisory committee, and the Australian Pharmaceutical Advisory Council (APAC), a representative council. Both groups had responsibility for advising the Federal Minister of Health. They both identified medication misadventure in residential aged care as a priority issue and through their recommendations the Government devoted funds to the development of best practice guidelines and research activity. Clinical pharmacy services in nursing-home and hostel settings were found to reduce the use of benzodiazepines, laxatives, NSAIDs and antacids leading to cost savings to the health system. Dose-administration aids were found to reduce error rates during medication administration, and the alteration of medications for administration to residents was found to be common practice and potentially problematic. Research in the Australian setting demonstrating effectiveness, as measured by changes in medication use or health outcomes, as well as actual or potential cost savings has been a critical success factor. In addition, prioritisation by government advisory committees, inquiries and policy documents, have assisted in the development of services from ideas in 1991 to nationally funded realities in 2002. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
42. Improving drug use: A case study of events which led to changes in use of flucloxacillin in...
- Author
-
Roughead, Elizabeth E. and Gilbert, Andrew L.
- Subjects
- *
ANTIBIOTICS , *DRUG utilization - Abstract
Presents a case study of events which led to changes in the use of the antibiotic, flucloxacillin in Australia. Adverse drug reaction reports; Pharmaceutical industry's advertising of flucloxacillin and cephalexin; Publication reports concerning flucloxacillin and adverse hepatic reactions.
- Published
- 1999
- Full Text
- View/download PDF
43. Proton-pump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia.
- Author
-
Roughead, Elizabeth E., Ramsay, Emmae N., Pratt, Nicole L., Ryan, Philip, and Gilbert, Andrew L.
- Subjects
PROTON pump inhibitors ,PNEUMONIA ,HOSPITAL care ,DISEASES in veterans - Abstract
The article presents a study which examines the association of proton-pump inhibitor (PPI) with hospitalisations for pneumonia and with antibiotic use in Australia. Conducted from January 1, 2002 to December 30, 2006, the study compared veterans exposed to PPIs with those not exposed. Researchers found that PPI use is linked to a small but significant increased risk of hospitalisation for pneumonia.
- Published
- 2009
- Full Text
- View/download PDF
44. Reduction in Use of Risperidone for Dementia in Australia Following Changed Guidelines.
- Author
-
Kalisch Ellett, Lisa M, Moffat, Anna K, Gadzhanova, Svetla, Pratt, Nicole L, Apajee, Jemisha, Woodward, Michael, and Roughead, Elizabeth E
- Subjects
RISPERIDONE ,ALZHEIMER'S disease ,ELDER care ,ALZHEIMER'S patients ,DEMENTIA - Abstract
Background: Risperidone is the only antipsychotic approved in Australia for the management of the behavioural and psychological symptoms of dementia (BPSD). In June 2015, the Australian Government Therapeutic Goods Administration (TGA) amended the indication to restrict use in BPSD to patients with Alzheimer's dementia for a maximum twelve-week duration. We aimed to determine whether the rate and duration of risperidone use for BPSD decreased following the regulatory changes. Methods: we conducted a study using the Australian Government Department of Veterans' Affairs administrative claims data and Pharmaceutical Benefits Scheme (PBS) 10% sample data. We included people aged 65 years or older and compared the rate and duration of risperidone use before and after the TGA labelling changes. Results: There was a sustained decrease in the trend of risperidone use for BPSD following the TGA labelling changes, with a monthly decrease of 1.7% in the aged care population, 0.5% in the community living population and 1.5% in the general older Australian population. Overall, in the 24 months post the TGA changes the reduction in the rate of use of risperidone ranged from 20% to 28% lower than compared to what the rate would have been without the TGA changes. The median duration of use of risperidone in aged-care residents decreased from 338 days in the year prior to the TGA labelling changes, to 240 days per person in the year after the changes. Conclusion: The TGA labelling changes were associated with a significant reduction in the rate of use of risperidone for BPSD in veterans living in both the aged care and community settings, and in the general older Australian population. The labelling changes were also associated with a reduced duration of risperidone use in aged care residents, although for most people the duration of use still exceeded the recommended 12-week maximum duration. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
45. Prevalence and Duration of Use of Medicines Recommended for Short-Term Use in Aged Care Facility Residents.
- Author
-
Kalisch Ellett, Lisa M., Kassie, Gizat M., Pratt, Nicole L., Kerr, Mhairi, and Roughead, Elizabeth E.
- Subjects
ELDER care ,OLDER people ,PROTON pump inhibitors ,URINARY tract infections ,NURSING home patients ,DRUGS - Abstract
Background: Multiple studies have assessed the appropriateness of the use of medicines for nursing home residents; however, few have included duration of use in their assessment. The aim of this study was to assess the level and duration of use of medications recommended for short-term use in residents of aged care facilities in Australia. Methods: Australian Government Department of Veterans' Affairs (DVA) administrative claims data were used for this study. Veterans eligible for all health services subsidised by DVA were followed for one year from 1 July 2015 to 30 June 2016. The number of days covered for each medicine was calculated by multiplying the number of prescriptions dispensed during the year by the pack duration for the medicine. The pack duration was calculated by dividing the quantity supplied at each dispensing by the usual number of doses per day in older people according to Australian prescribing guidelines. The proportion of patients using each medicine and the number of days covered during the study period were determined. Results: 14, 237 residents met the inclusion criteria. One in five participants were dispensed antipsychotics, and the median duration of use was 180 days in the one-year period. More than one-third were dispensed a benzodiazepine, and the median duration of use was 240 days in the year. Half were dispensed an opioid analgesic with a median duration of use of 225 days in the year. Fifty-two percent were dispensed proton pump inhibitors with a median duration of use of 360 days in the year. A quarter received an antibiotic recommended for the management of urinary tract infection, with a median duration of use of 14 days in the year. Conclusion: Long-term use of antipsychotics, benzodiazepines, opioid analgesics and proton pump inhibitors is common in aged care residents. Ensuring appropriate duration of use for these medicines is necessary to reduce risk of harm. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
46. Response to Lertxundi and Colleagues.
- Author
-
Kalisch Ellett, Lisa M., Pratt, Nicole L., Ramsay, Emmae N., Barratt, John D., and Roughead, Elizabeth E.
- Subjects
PARASYMPATHOMIMETIC agents ,RESEARCH methodology ,RISK assessment - Abstract
The authors offer a reply to a letter to the editor from Unax Lertxundi, Saioa Domingo-Echaburu, Rafael Hernandez, Javier Peral-Aguirregoitia, and Juan Medrano in the current issue responding to their article "Multiple anticholinergic medication use and risk of hospital admission for confusion or dementia," which appeared in the publication in 2014.
- Published
- 2015
- Full Text
- View/download PDF
47. Suboptimal medication-related quality of care preceding hospitalisation of older patients.
- Author
-
Caughey, Gillian E, Kalisch Ellett, Lisa M, Goldstein, Stan, and Roughead, Elizabeth E
- Subjects
DRUG side effects ,HOSPITAL care ,VETERANS ,MEDICAL quality control ,DISEASE prevalence ,RETROSPECTIVE studies - Abstract
Objective: To examine the prevalence of suboptimal medication-related processes of care before the hospitalisation of older patients.Design and Setting: We conducted a retrospective cohort study using a clinical indicator set related to medication management that has been validated by an expert panel as consisting of suboptimal aspects of medication use that clinicians should be able to foresee and avoid. Australian Government Department of Veterans' Affairs administrative claims data between 1 July 2007 and 30 June 2012 were analysed according to these clinical indicators to assess medication-related processes of care preceding hospitalisation.Participants: Veterans with one or more hospitalisations in Australia for a condition defined by the clinical indicator set.Main Outcome Measure: Prevalence of suboptimal medication-related processes of care before hospitalisation as a proportion of all hospitalisations defined by diagnoses in the clinical indicator set.Results: During the 5-year study period, there were 164,813 hospitalisations with primary diagnoses for conditions included in the clinical indicator set, encompassing 83,430 patients. The overall proportion of hospitalisations that were preceded by suboptimal medication-related processes of care was 25.2% (41,546 hospitalisations); 34.5% of patients (28,807 patients) had at least one hospitalisation and 10.4% (8640 patients) had two or more hospitalisations preceded by suboptimal medication-related processes of care. At least one in 10 hospitalisations for chronic heart failure, ischaemic stroke, asthma, gastrointestinal ulcer or bleeding, fracture, renal failure or nephropathy, hyperglycaemia or hypoglycaemia were preceded by suboptimal medication-related processes of care.Conclusions: This study highlights conditions for which there are evidence-practice gaps in medication management in the older population. Routine prospective monitoring of these evidence-based, validated, medication-related clinical indicators provides a means for quality improvement in the management of common chronic conditions. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
48. Chronic disease management: does the disease affect likelihood of care planning?
- Author
-
Vitry, Agnes I., Roughead, Elizabeth E., Ramsay, Emmae N., Ryan, Philip, Caughey, Gillian E., Esterman, Adrian, Shakib, Sepehr, Gilbert, Andrew L., and McDermott, Robyn
- Subjects
- *
CHRONIC disease treatment , *TREATMENT of diabetes , *CHI-squared test , *COMPARATIVE studies , *CONFIDENCE intervals , *FAMILY medicine , *HEALTH care teams , *LONGITUDINAL method , *VETERANS , *POISSON distribution , *RESEARCH funding , *T-test (Statistics) , *MATHEMATICAL variables , *SOCIOECONOMIC factors - Abstract
Objective. To compare the demographic, socioeconomic, and medical characteristics of patients who had a General Practitioner Management Plan (GPMP) with those for patients without GPMP. Methods. Cohort study of patients with chronic diseases during the time period 1 July 2006 to 30 June 2008 using the Australian Department of Veterans' Affairs (DVA) claims database. Results. Of the 88 128 veterans with chronic diseases included in the study, 23 015 (26%) veterans had a GPMP and 11 089 (13%) had a Team Care Arrangement (TCA). Those with a GPMP had a higher number of comorbidities (P < 0.001), and a higher use of services such as health assessment and medicine review (P < 0.001) than did those without GPMP. Diabetes was associated with a significantly increased use of GPMP compared with all other chronic diseases except heart failure. Conclusions. GPMPs are used in a minority of patients with chronic diseases. Use is highest in people with diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
49. Cardiac Implantable Electronic Devices: Reoperations and the Competing Risk of Death.
- Author
-
Gillam, Marianne H., Pratt, Nicole L., Inacio, Maria C.S., Shakib, Sepehr, Caughey, Gillian E., Sanders, Prashanthan, Lau, Dennis H., and Roughead, Elizabeth E.
- Subjects
- *
ARTIFICIAL implants , *ELECTRONIC equipment , *CARDIAC pacemakers , *COMPETING risks , *MEDICAL care , *IMPLANTABLE cardioverter-defibrillators , *OLDER patients , *RETROSPECTIVE studies , *CARDIAC pacing , *REOPERATION , *ELECTRONICS - Abstract
Background: The use of cardiac implantable electronic devices (CIED), which includes pacemakers, implantable cardioverter-defibrillators (ICD), cardiac resynchronisation therapy pacemakers (CRT-P) and cardiac resynchronisation therapy defibrillators (CRT-D) has increased over the past 20 years, but there is a lack of real world evidence on the longevity of these devices in the older population which is essential to inform health care delivery and support clinical decisions.Methods and Results: We conducted a retrospective cohort study using data from the Australian Government Department of Veterans' Affairs database. The cohort consisted of people who had a CIED procedure between 2005 and 2015. The cumulative risk of generator replacement/reoperations was estimated accounting for the competing risk of death. A total of 16,662 patients were included. In pacemaker recipients with an average age of 85 years, the 5-year risk of reoperation ranged from 2.8% in single chamber, 3.6% in dual chamber to 7.6% in CRT-P recipients, while the 5-year risk of dying with the index pacemaker in situ was 63% in single chamber, 46% in dual chamber and 56% in CRT-P recipients. In defibrillator recipients with an average age of 80 years, the 5-year risk of reoperation ranged from 11% in single chamber, 13% in dual chamber to 24% in CRT-D recipients, while the 5-year risk of dying with the index defibrillator in situ was 46% in single chamber, 40% in dual chamber and 41% in CRT-D recipients.Conclusion: In this cohort of older patients the 5-year risk of generator reoperation was low in pacemaker recipients whereas up to one in four CRT-D recipients would have a reoperation within 5 years. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
50. Central Nervous System-Acting Medicines and Risk of Hospital Admission for Confusion, Delirium, or Dementia.
- Author
-
Kalisch Ellett, Lisa M., Pratt, Nicole L., Ramsay, Emmae N., Sluggett, Janet K., Barratt, John D., and Roughead, Elizabeth E.
- Subjects
- *
HOSPITAL care of older people , *CENTRAL nervous system , *COMBINATION drug therapy , *COGNITION , *COGNITION disorders , *CONFIDENCE intervals , *DELIRIUM , *DEMENTIA , *DRUGS , *DOSE-effect relationship in pharmacology , *HOSPITAL admission & discharge , *LONGITUDINAL method , *VETERANS , *PATIENTS , *RESEARCH funding , *RELATIVE medical risk , *INDEPENDENT living , *RETROSPECTIVE studies , *POLYPHARMACY , *DESCRIPTIVE statistics , *OLD age - Abstract
Background Most studies assessing the effect of central nervous system (CNS)-acting medicines on cognitive disturbances have focused on the use of individual medicines. The impact on cognitive function when another CNS-acting medicine is added to a patient's treatment regimen is not well known. Objective To determine risk of hospitalization for confusion, delirium, or dementia in older people associated with increasing numbers of CNS-acting medicines taken concurrently, as well as the number of standard doses taken each day (measured as defined daily doses). Design Retrospective cohort study, from July 2011 to June 2012, using health claims data. Setting Australian veteran population. Participants A total of 74,321 community-dwelling individuals aged 65 years and over, who were dispensed at least 1 CNS-acting medicine in the year before study entry. Patients with prior hospitalization for confusion or delirium, and those with dementia or receiving palliative care, were excluded. Main outcome measure Hospitalization for confusion, delirium, or dementia. Results Over the 1-year study period, 401 participants were hospitalized with confusion, delirium, or dementia. Adjusted analyses showed the risk of hospitalization was 2.4 times greater with the use of 2 CNS-acting medicines compared with no use [incident rate ratio (IRR) 2.39, 95% confidence interval (CI) 1.79–3.19, P < .001], and more than 19 times greater when 5 or more CNS-acting medicines were taken concurrently (IRR 19.35, 95% CI 11.10–33.72, P < .001). Similarly, the risk of hospitalization was significantly increased among patients taking between 1.0 and 1.9 standard doses per day (IRR 2.64, 95% CI 1.99–3.50, P < .001) and between 2.0 and 2.9 standard doses per day (IRR 3.43, 95% CI 2.07–5.69, P < .001) compared with no use. Conclusions Use of multiple CNS-acting medicines or higher doses is associated with an increased risk of hospitalization for confusion, delirium, or dementia. Health care professionals need to be alert to the contribution of CNS-acting medicines among patients presenting with confusion or delirium and consider strategies to reduce treatment burden where possible. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.